Chapin Davis Inc. Boosts Stock Position in GSK plc (NYSE:GSK)

Chapin Davis Inc. lifted its stake in shares of GSK plc (NYSE:GSK) by 2.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 14,591 shares of the pharmaceutical company’s stock after purchasing an additional 360 shares during the quarter. Chapin Davis Inc.’s holdings in GSK were worth $562,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in GSK. 1832 Asset Management L.P. grew its holdings in shares of GSK by 9.1% in the first quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock worth $132,000 after purchasing an additional 257 shares during the last quarter. Personal CFO Solutions LLC grew its holdings in GSK by 2.7% in the 4th quarter. Personal CFO Solutions LLC now owns 10,087 shares of the pharmaceutical company’s stock worth $374,000 after acquiring an additional 263 shares during the last quarter. Boltwood Capital Management increased its position in shares of GSK by 2.5% in the second quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock valued at $429,000 after acquiring an additional 270 shares during the period. J.W. Cole Advisors Inc. raised its stake in shares of GSK by 4.7% during the first quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company’s stock valued at $261,000 after acquiring an additional 271 shares during the last quarter. Finally, First Affirmative Financial Network boosted its holdings in shares of GSK by 4.7% during the second quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock worth $245,000 after purchasing an additional 283 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Up 0.6 %

GSK stock traded up $0.26 during midday trading on Friday, hitting $41.28. The stock had a trading volume of 3,145,786 shares, compared to its average volume of 3,581,986. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.58. The firm has a market cap of $85.55 billion, a price-to-earnings ratio of 14.96, a price-to-earnings-growth ratio of 1.32 and a beta of 0.64. The business has a 50-day moving average of $39.73 and a two-hundred day moving average of $41.49. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be issued a $0.3843 dividend. This represents a $1.54 dividend on an annualized basis and a yield of 3.72%. The ex-dividend date is Friday, August 16th. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is 54.71%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GSK shares. Berenberg Bank upgraded GSK to a “strong-buy” rating in a report on Thursday, June 20th. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Citigroup raised GSK to a “strong-buy” rating in a research note on Monday, June 24th. The Goldman Sachs Group started coverage on shares of GSK in a research report on Thursday, May 30th. They set a “neutral” rating and a $47.00 price objective on the stock. Finally, Jefferies Financial Group raised their target price on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Three analysts have rated the stock with a hold rating, two have given a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.